Lisata Therapeutics, Inc. filings document material events, operating updates, and capital-structure matters for a clinical-stage pharmaceutical company focused on certepetide and related solid-tumor therapy development. Recent Form 8-K disclosures include financial results, Regulation FD materials, corporate presentations, material agreements, shareholder-voting matters, governance topics, and clinical or regulatory disclosures.
The filing record also documents changes to certepetide commercialization rights, including the termination of a Greater China license and collaboration agreement related to research, development, and commercialization of the product candidate. These disclosures frame Lisata’s formal reporting around program development, partnership economics, public-company governance, and transaction-related capital structure matters.
Lisata Therapeutics, Inc. completed its acquisition of Marea Therapeutics on September 17, 2026, issuing former Marea stockholders 1,793,129 common shares and 211,365.213 Series C preferred shares. Each preferred share is convertible into 1,000 common shares, subject to stockholder approval and beneficial ownership limitations. Lisata separately sold 150,867.995 Series C preferred shares in a private placement for approximately $225 million at $1,491.37 per preferred share. Immediately after the financing, legacy Lisata equityholders held approximately 2.39% of the common stock on a fully diluted, as-converted basis; former Marea equityholders held 59.54%, and private-placement investors held 38.07%.
At the November 9, 2026 virtual annual meeting, stockholders will vote on conversion approval, a proposed 1-for-5 to 1-for-15 reverse split, equity and employee stock-purchase plans, directors, auditor ratification, executive compensation, and possible adjournment. If required approvals are not obtained by six months after the Series C’s initial issuance, holders would be entitled to require cash settlement at fair value. A change to Marea Therapeutics and ticker MREA is expected only if the required stockholder matters and Nasdaq Listing Application are approved.
Lisata Therapeutics, Inc. director Jeffrey S. Farrow reported no securities beneficially owned, with 0 shares held directly as of October 13, 2026.
Lisata Therapeutics increased its board from seven to eight members and appointed Jeffrey Farrow as a Class III director effective October 13, 2026. His initial term expires at the company’s 2028 annual meeting, and he also joined the Audit Committee. The board determined that Farrow is independent under Nasdaq listing rules.
Farrow has served as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals since April 2023 and as a director of Clover Biopharmaceuticals and Achieve Life Sciences. Lisata described him as having more than 15 years of public-company financial leadership across development, approval and commercial launch. He previously served as chief financial officer of Global Blood Therapeutics, ZS Pharma and Hyperion Therapeutics.
Lisata Therapeutics, Inc. completed its acquisition of Marea Therapeutics on September 17, 2026, issuing Marea holders 1,793,129 common shares and 211,365.213 Series C preferred shares. Each preferred share is convertible into 1,000 common shares after approval of Proposals 3 and 4, subject to beneficial ownership limitations. On September 18, Lisata sold 150,867.995 Series C preferred shares for approximately $225 million in gross proceeds.
Lisata expects to use the private-placement proceeds primarily to advance MAR001/005 and MAR002; topline data from a Phase 2b trial in severe hypertriglyceridemia and a Phase 2 trial in acromegaly are expected in the fourth quarter of 2027. At the November 9, 2026 virtual meeting, stockholders will vote on conversion, a reverse split at a Board-selected ratio from 1-for-5 to 1-for-10, the 2026 equity incentive and employee stock purchase plans, directors, auditor ratification, executive compensation and adjournment. If required approvals are not obtained by six months after initial Series C issuance, holders may require cash settlement at fair value. If required approvals and Nasdaq’s listing application are approved, Lisata expects to change its name to Marea Therapeutics and use symbol MREA.
Lisata Therapeutics, Inc. (LSTA) reported an exempt offering under Rule 506(b), with a total amount sold of $351,903,103 and $0 remaining to be sold. The notice lists equity and securities to be acquired upon exercise of an option, warrant or other right to acquire a security. The first sale was on September 17, 2026, and reported finders’ fees were $0.
Lisata Therapeutics, Inc. director Ted W. Love reported direct holdings on September 17, 2026, of 19,260 common shares and Series C Non-Voting Convertible Preferred Stock representing 2,270,316 underlying common shares. The reported shares were received in exchange for 2,354,899 shares of Marea Therapeutics, Inc. common stock in connection with the merger. Some of the reported common and preferred shares are subject to an issuer repurchase right that lapses under time- or milestone-based vesting conditions. Each preferred share automatically converts into 1,000 common shares upon issuer stockholder approval, subject to a holder-established beneficial ownership limitation between 4.9% and 19.99% of outstanding common stock.
Lisata Therapeutics, Inc. reports that its President & COO, Joshua Lehrer-Graiwer, held 2,540,002 common shares underlying Series C preferred stock and 21,548 common shares directly as of September 17, 2026. The Lehrer Family Irrevocable GST Exempt Trust held 737,919 common shares underlying preferred stock and 6,260 common shares indirectly. The positions were received in the Marea Therapeutics merger exchange; a portion is subject to repurchase rights that lapse under time- or milestone-based vesting conditions.
LISATA THERAPEUTICS, INC. (symbol: LSTA) is the issuer of record for a Form 8-K filing submitted to the SEC.
LISATA THERAPEUTICS, INC. (LSTA) has a new large shareholder disclosure. Investor Justin Branham filed a Schedule 13G reporting beneficial ownership of 462,148.68 shares of Lisata Therapeutics common stock, par value $0.001 per share. This position represents 5.1% of the outstanding common stock.
Branham reports sole voting and dispositive power over all 462,148.68 shares and no shared voting or dispositive power. The filing identifies Branham as a United States citizen and lists the holding as common stock only.